April 5, 2005

Injectable Drug, Combined with Counseling, Shows Promise in Treating Alcohol Dependence

(Philadelphia, PA) -- Alcohol dependence is a major public health problem, ranking as the fourth leading cause of disability worldwide, according to the World Health Organization’s Global Burden of Disease project. In the United States, it is believed to contribute to more than 100,000 preventable deaths a year. Now, researchers from the University of Pennsylvania School of Medicine, in conjunction with 23 other sites nationwide, have found that long-acting injections of the drug naltrexone, when added to counseling, significantly reduced heavy drinking in patients being treated for alcohol dependence.

Study results show that the median number of heavy-drinking days was reduced from 19 days in the month prior to the study to three days per month over the six months of treatment. The results will be published in the April 6 issue of the Journal of the American Medical Association.

“It is so important that our field find new treatments for alcohol dependence,” says Helen Pettinati, PhD, Research Professor in Penn’s Department of Psychiatry, Director, Treatment Research Division in the Center for the Study of Addictions, and lead investigator for Penn’s component of the trial. “Long-acting naltrexone represents a promising new development for treatment, and I hope that it can play a role in helping the large number of individuals in the U.S. who suffer from alcohol dependence.”

Naltrexone was approved in pill form by the U.S. Food and Drug Administration in 1994 for treating alcohol dependence. It belongs to a class of drugs called opioid antagonists, for treating alcohol dependence. Although many clinical trials have shown that oral naltrexone can be effective in treating alcohol dependence, its use in clinical practice has been limited, in part because the drug was given as a pill that patients have to take daily.

“Alcoholism is a serious disease that destroys lives. As we learn more about how the brain is affected by alcohol, we are discovering how best to provide treatment -- like adding a safe medication to counseling. A long-acting injectable, which eliminates the burden of daily pill taking, will open new doors for our patients and give hope to them and their families,” adds Dr. Pettinati.

A total of 627 alcohol-dependent patients were randomly assigned to receive either an injection of long-acting naltrexone or a placebo injection; 624 ultimately received at least one injection. In addition to an injection, all participants received low-intensity counseling consisting of 12 sessions during the six-month study, in addition to study medication. Long-acting naltrexone was associated with a reduction in heavy drinking within the first month of treatment, and this response was maintained over the six-month treatment period. In addition, long-acting naltrexone was generally well tolerated and side effects were predominantly mild and decreased over time. (The three most common side effects reported were nausea, headache and fatigue.)

The study was one of the largest trials of a medication for alcohol dependence and was conducted at 24 sites nationwide, including public, private hospitals and Veterans Administration clinics and tertiary-care medical centers. Other study authors included researchers from the medical schools at the University of Connecticut, Yale University, and Harvard University, and from Alkermes Incorporated, a biotechnology company based in Cambridge, Mass., that manufactures the long-acting naltrexone formulation (Vivitrex) used in the study.

This study was funded by Alkermes Incorporated. Dr. Pettinati received research support from Alkermes to conduct this study at Penn, and she also is an external advisor to the company.

Persons with alcohol and drug dependence who are interested in obtaining no-cost treatment in a clinical trial should call Penn’s Treatment Research Center at the 215-243-9959.

###

PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System.

Penn’s School of Medicine is ranked #3 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report’s most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

Penn Health System is comprised of: its flagship hospital, the Hospital of the University of Pennsylvania, consistently rated one of the nation’s “Honor Roll” hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; Presbyterian Medical Center; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home health care and hospice.

This release is available online at http://www.uphs.upenn.edu/news/News_Releases/apr05/naltrexone.htm